Gonadic Function and Pubertal Development in Female Patients With Classic Galactosemia

IRCCS Azienda Ospedaliero-Universitaria di Bologna60 enrolled

Overview

Newborn screening and a galactose-free diet have improved early outcomes in galactosemia, but long-term issues such as primary ovarian insufficiency (POI) remain significant. This study aims to clarify clinical, hormonal, developmental, and fertility-related factors in affected girls through a large multicenter Italian cohort.

Newborn screening for galactosemia and adherence to a galactose-free diet have greatly reduced acute neonatal symptoms, leading to high survival rates. However, despite good therapeutic compliance, long-term complications-especially primary ovarian insufficiency (POI) and its related morbidity-remain common. Because galactosemia is rare, identifying factors underlying ovarian dysfunction and fertility-preservation options has been challenging. A large, homogeneous multicenter Italian study could help clarify unresolved aspects of POI in females with classic galactosemia. Primary aims: * Compare clinical, auxological, and hormonal features of girls with galactosemia to those of the general population at key stages of pubertal development. * Identify potential factors contributing to POI. * Describe fertility-related characteristics in affected patients. Secondary aims: * Determine the proportion of patients who reach their familial height target. * Assess quality of life and psycho-emotional adjustment. * Evaluate psychomotor and cognitive development.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Galactosemia

Eligibility

Sex: FEMALEMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients followed at participating Pediatric Endocrinology and Inherited Metabolic Disease Centers, born between January 1st, 1980 and December 31st, 2024, with a diagnosis of classic galactosemia and confirmed by genetic testing. * Obtaining informed consent. Exclusion Criteria: * Patients with known chromosomal abnormalities (e.g., trisomy 21, Turner syndrome, Fragile X syndrome, Kabuki syndrome, or other genetic conditions associated with pubertal disorders); * Patients with primary ovarian insufficiency due to causes other than galactosemia.

Locations (19)

SSD Nutrizione Clinica e Metabolismo - IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy, Italy

Outcomes

Primary Outcomes

To compare clinical and auxological features, as well as hormonal levels, of patients with a diagnosis of classic galactosemia with those of the general population at key stages of pubertal development

Mean laboratoristic parametres (FSH, LH, estradiol, AMH, inhibin-B)

Time frame: During minipuberty (3-18 months), childhood (18 months-10 years), puberty (from 10 years to menarche onset), and adulthood (before Menopause).

To identify and describe potential factors contributing to the development of primary ovarian insufficiency (POI) in female patients with classic galactosemia

Presence of POI (yes/no)

Time frame: At puberty (from 10 years to menarche onset), and at adulthood (before Menopause)

Secondary Outcomes

To determine the proportion of patients with classic galactosemia who achieve their familial height target

Final Height (cm)

Time frame: at adulthood (before Menopause)

Central Contacts

Rita Ortolano

CONTACT

00390512144816 rita.ortolano@aosp.bo.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.